193 related articles for article (PubMed ID: 17123665)
1. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role.
Desideri G; Cipollone F; Necozione S; Marini C; Lechiara MC; Taglieri G; Zuliani G; Fellin R; Mezzetti A; di Orio F; Ferri C
Neurobiol Aging; 2008 Mar; 29(3):348-56. PubMed ID: 17123665
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease.
Buchhave P; Janciauskiene S; Zetterberg H; Blennow K; Minthon L; Hansson O
Neurosci Lett; 2009 Jan; 450(1):56-9. PubMed ID: 18996438
[TBL] [Abstract][Full Text] [Related]
3. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease.
Türker S; Güneri S; Akdeniz B; Ozcan MA; Baris N; Badak O; Kirimli O; Yüksel F
Am J Cardiol; 2006 Jan; 97(2):198-202. PubMed ID: 16442363
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease.
Ait-ghezala G; Abdullah L; Volmar CH; Paris D; Luis CA; Quadros A; Mouzon B; Mullan MA; Keegan AP; Parrish J; Crawford FC; Mathura VS; Mullan MJ
Cytokine; 2008 Nov; 44(2):283-7. PubMed ID: 18835787
[TBL] [Abstract][Full Text] [Related]
6. Enhanced plasma soluble CD40 ligand levels in essential hypertensive patients with blunted nocturnal blood pressure decrease.
Desideri G; Cipollone F; Valeri L; Grassi D; Necozione S; Croce G; Passacquale G; Garofalo A; Lippi C; Mezzetti A; Ferri C
Am J Hypertens; 2007 Jan; 20(1):70-6; discussion 77. PubMed ID: 17198914
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychometric tests in cross sectional and longitudinal studies - a regression analysis of ADAS - cog, SKT and MMSE.
Ihl R; Grass-Kapanke B; Jänner M; Weyer G
Pharmacopsychiatry; 1999 Nov; 32(6):248-54. PubMed ID: 10599935
[TBL] [Abstract][Full Text] [Related]
8. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study.
Tully AM; Roche HM; Doyle R; Fallon C; Bruce I; Lawlor B; Coakley D; Gibney MJ
Br J Nutr; 2003 Apr; 89(4):483-9. PubMed ID: 12654166
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease.
Lim PS; Wu MY; Chien SW; Wu TK; Liu CS; Hu CY; Chang HC; Pai MA
Nephrology (Carlton); 2008 Dec; 13(8):677-83. PubMed ID: 19019166
[TBL] [Abstract][Full Text] [Related]
10. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation.
Ferro D; Loffredo L; Polimeni L; Fimognari F; Villari P; Pignatelli P; Fuster V; Violi F
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2763-8. PubMed ID: 17901373
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation.
Duygu H; Barisik V; Kurt H; Turk U; Ercan E; Kose S
Europace; 2008 Feb; 10(2):210-4. PubMed ID: 18184662
[TBL] [Abstract][Full Text] [Related]
12. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
14. Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction.
Dominguez-Rodriguez A; Abreu-Gonzalez P; Garcia-Gonzalez MJ; Kaski JC
Thromb Res; 2007; 121(3):293-9. PubMed ID: 17521712
[TBL] [Abstract][Full Text] [Related]
15. Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria.
Ferroni P; Guagnano MT; Falco A; Paoletti V; Manigrasso MR; Michetti N; Santilli F; Guadagni F; Basili S; Davì G
Clin Sci (Lond); 2008 Mar; 114(6):449-55. PubMed ID: 17988217
[TBL] [Abstract][Full Text] [Related]
16. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
17. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.
Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L;
Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368
[TBL] [Abstract][Full Text] [Related]
18. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes.
Tousoulis D; Antoniades C; Nikolopoulou A; Koniari K; Vasiliadou C; Marinou K; Koumallos N; Papageorgiou N; Stefanadi E; Siasos G; Stefanadis C
Eur J Clin Invest; 2007 Aug; 37(8):623-8. PubMed ID: 17635572
[TBL] [Abstract][Full Text] [Related]
19. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease.
Kim TS; Lim HK; Lee JY; Kim DJ; Park S; Lee C; Lee CU
Neurosci Lett; 2008 May; 436(2):196-200. PubMed ID: 18378084
[TBL] [Abstract][Full Text] [Related]
20. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndromes.
Yan JC; Zhu J; Gao L; Wu ZG; Kong XT; Zong RQ; Zhan LZ
Clin Chim Acta; 2004 May; 343(1-2):155-9. PubMed ID: 15115688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
